FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Saag

Research Profile

Disorders

Chemicals & Drugs

Living Beings

HIV-1
HIV

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sadeep Shrestha; Joseph J Eron; Derek C Johnson; William C Mathews; Sonia Napravnik; Jill Palchinsky; DC Porter; Erin Reid; Michael S Saag
Short Communication: Lack of Occult HIV Infection Among Non-AIDS-Defining Cancer Patients in Three Academic Oncology Clinics in the United States.
Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Yazdan Yazdanpanah; Edwin DeJesus; Mark J DiNubile; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK.
Laura H Bachmann; Huey Chen; Hongjiang Gao; Diane M Grimley; James L Raper; Scott D Rhodes; Michael S Saag; Inmaculada Aban; Edward W Hook
Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV-positive men who have sex with men (MSM) in a primary care setting.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Saag (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sadeep Shrestha; Joseph J Eron; Derek C Johnson; William C Mathews; Sonia Napravnik; Jill Palchinsky; DC Porter; Erin Reid; Michael S Saag
Short Communication: Lack of Occult HIV Infection Among Non-AIDS-Defining Cancer Patients in Three Academic Oncology Clinics in the United States.
AIDS research and human retroviruses 2013;29(6):887-91.
2013: Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Yazdan Yazdanpanah; Edwin DeJesus; Mark J DiNubile; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK.
Journal of acquired immune deficiency syndromes (1999) 2013;63(1):77-85.
2013: Laura H Bachmann; Huey Chen; Hongjiang Gao; Diane M Grimley; James L Raper; Scott D Rhodes; Michael S Saag; Inmaculada Aban; Edward W Hook
Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV-positive men who have sex with men (MSM) in a primary care setting.
AIDS education and prevention : official publication of the International Society for AIDS Education 2013;25(2):87-101.
2013: James H Willig; Todd Correll; Amit Duggal; William Guyer; Michael J Mugavero; Christa R Nevin; Michael S Saag; Andrew Westfall; Timothy Juday
Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes.
AIDS research and human retroviruses 2013;29(4):698-703.
2013: James H Willig; Ashutosh Tamhane; Sara-Anne Wilkins; Michael J Mugavero; Laura A Napolitano; Christa R Nevin; James L Raper; Michael S Saag
Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
AIDS research and human retroviruses 2013;29(1):105-11.
2012: David J Kim; Michael J Mugavero; James L Raper; Christine Ritchie; Michael S Saag; Andrew Westfall; Amanda Lynn Willig; Greer A Burkholder; Eric Chamot; Heidi M Crane; James H Willig
Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering.
Journal of acquired immune deficiency syndromes (1999) 2012;61(5):600-5.
2012: Michael S Saag
New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings.
Topics in antiviral medicine 2012;20(5):162-7.
2012: Michael S Saag
Editorial commentary. Viva no difference!
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012;55(9):1252-4.
2012: Jessica S Merlin; Robert Gross; Wynne E Norton; James L Raper; Christine S Ritchie; Michael S Saag; Andrew Westfall; James H Willig; Anne Zinski; Michael J Mugavero
Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure.
Journal of acquired immune deficiency syndromes (1999) 2012;61(2):164-70.
2012: Jeffrey S A Stringer; Frank B Williams; Mark J Giganti; Jens W Levy; Lloyd Mulenga; Priscilla Mulenga; Patrick Musonda; Albert J Mwango; Stewart E Reid; Michael S Saag; Elizabeth M Stringer; Benjamin H Chi
Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.
International journal of epidemiology 2012;41(2):448-59.
2012: Tyler Tate; Amanda Lynn Willig; James H Willig; Mirjam C Kempf; Linda Moneyham; James L Raper; Michael S Saag; Michael J Mugavero
HIV infection and obesity: where did all the wasting go?
Antiviral therapy 2012;17(7):1281-9.
2012: Michael J Mugavero; Wynne E Norton; James L Raper; K Rivet Amico; Heidi M Crane; Julia C Dombrowski; Mari M Kitahata; Andrew Westfall; James H Willig; Anne Zinski; Michael S Saag
Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention.
Journal of acquired immune deficiency syndromes (1999) 2012;59(1):86-93.
2011: Michael S Saag
HIV now firmly established in the Middle Ages.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(11):1140-2.
2011: Marguerite Ryan Irvin; Jerome I Rotter; Michael S Saag; Rebecca Scherzer; Sadeep Shrestha; Kent D Taylor; Hemant K Tiwari; Laura K Vaughan; Howard W Wiener; Yii-Der I Chen; Carl Grunfeld; Talin Haritunians; Donna K Arnett
Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men.
Pharmacogenetics and genomics 2011;21(12):798-807.
2011: Michael J Mugavero; Sonia Napravnik; Michael S Saag; James H Willig; Stephen R Cole; Heidi M Crane; Steven G Deeks; Joseph J Eron; Mari M Kitahata; Bryan Lau; Richard D Moore
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(9):927-35.
2011: Michael J Mugavero; Javier Murillas; Sonia Napravnik; Andrew Phillips; Heather J Ribaudo; Sharon A Riddler; Michael S Saag; Colette Smith; Jonathan A C Sterne; Christoph Wyen; Sophie Abgrall; Juan Berenguer; Geneviève Chêne; Antonella d'Arminio Monforte; Frank de Wolf; Pere Domingo; M John Gill; Jodie L Guest; Roy M Gulick; Huldrych F Günthard; Ross Harris; Richard Haubrich; Robert Hogg; Mari M Kitahata; Margaret May
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Journal of acquired immune deficiency syndromes (1999) 2011;58(3):253-60.
2011: Christa R Nevin; James L Raper; Michael S Saag; Inmaculada B Aban; Jeroan Allison; David Jackson; Hui-Yi Lin; Michael J Mugavero; Jiatao Ye; James H Willig
The role of toxicity-related regimen changes in the development of antiretroviral resistance.
AIDS research and human retroviruses 2011;27(9):957-63.
2011: Paula S Seal; James H Willig; Jeroan J Allison; Eric Chamot; David A Jackson; Mirjam C Kempf; Christa R Nevin; James L Raper; Michael S Saag; Joseph E Schumacher; Michael J Mugavero
Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality.
Journal of general internal medicine 2011;26(7):745-50.
2011: Noah C Godwin; James H Willig; Christa R Nevin; Hui-Yi Lin; Jeroan Allison; Kathy Gaddis; Jennifer Peterson; Michael S Saag; Michael J Mugavero; James L Raper
Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications.
Health services research 2011;46(3):982-95.
2011: Mari M Kitahata; Chad J Achenbach; Michael S Saag
Age at cancer diagnosis among persons with AIDS.
Annals of internal medicine 2011;154(9):642-3; author reply 643.
2011: Michael J Mugavero; Wynne E Norton; Michael S Saag
Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52 Suppl 2():S238-46.
2011: Heidi M Crane; Carl Grunfeld; James H Willig; Michael J Mugavero; Stephen Van Rompaey; Richard D Moore; Benigno Rodriguez; Betsy J Feldman; Michael M Lederman; Michael S Saag; Mari M Kitahata
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
AIDS (London, England) 2011;25(2):185-95.
2011: David E Vance; Michael J Mugavero; James H Willig; James L Raper; Michael S Saag
Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life.
The Journal of the Association of Nurses in AIDS Care : JANAC 2011;22(1):17-25.
2010: James H Willig; Inmaculada B Aban; Christa R Nevin; Jiatao Ye; James L Raper; James A McKinnel; Lori L Delaitsch; Joseph M Mrus; Guy R De La Rosa; Michael J Mugavero; Michael S Saag
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.
AIDS research and human retroviruses 2010;26(12):1279-85.
2010: James L Raper; James H Willig; Hui-Yi Lin; Jeroan J Allison; M Bennet Broner; Michael J Mugavero; Michael S Saag
Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;51(6):718-24.
2010: Frank Wolschendorf; Alexandra Duverger; Jennifer Jones; Frederic H Wagner; Jason Huff; William H Benjamin; Michael S Saag; Michael Niederweis; Olaf Kutsch
Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.
Journal of virology 2010;84(17):8712-20.
2010: Justin S Routman; James H Willig; Andrew Westfall; Sarah R Abroms; Mohit Varshney; Sunil Adusumilli; Jeroan J Allison; Karen G Savage; Michael S Saag; Michael J Mugavero
Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(4):574-84.
2010: James H Willig; Juan Echevarria; Andrew Westfall; David Iglesias; German Henostroza; Carlos Seas; Michael J Mugavero; Jeroan Allison; Jorge Paz; Fiorella Hernandez; Cristina Tomatis; Michael S Saag; Eduardo Gotuzzo
Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing.
Journal of acquired immune deficiency syndromes (1999) 2010;53(2):215-21.
2010: James A McKinnell; James H Willig; Andrew O Westfall; Christa Nevin; Jeroan J Allison; James L Raper; Michael J Mugavero; Michael S Saag
Antiretroviral prescribing patterns in treatment-naïve patients in the United States.
AIDS patient care and STDs 2010;24(2):79-85.
2010: Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.
American journal of epidemiology 2010;171(2):198-205.
2010: John R Koethe; Andrew O Westfall; Dora K Luhanga; Gina M Clark; Jason D Goldman; Priscilla L Mulenga; Ronald A Cantrell; Benjamin H Chi; Isaac Zulu; Michael S Saag; Jeffrey S A Stringer
A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics.
PloS one 2010;5(3):e9680.
2009: Ha Youn Lee; Elena E Giorgi; Brandon F Keele; Brian Gaschen; Gayathri S Athreya; Jesus F Salazar-Gonzalez; Kimmy T Pham; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Beatrice H Hahn; George M Shaw; Bette T Korber; Tanmoy Bhattacharya; Alan S Perelson
Modeling sequence evolution in acute HIV-1 infection.
Journal of theoretical biology 2009;261(2):341-60.
2009: James A McKinnell; Michael S Saag
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
Current opinion in HIV and AIDS 2009;4(6):513-7.
2009: Mirjam C Kempf; Maria Pisu; Anastasiya Dumcheva; Andrew Westfall; J Michael Kilby; Michael S Saag
Gender differences in discontinuation of antiretroviral treatment regimens.
Journal of acquired immune deficiency syndromes (1999) 2009;52(3):336-41.
2009: James A McKinnell; Hui-Yi Lin; Christa N Nevin; James H Willig; Graeme McFarland; Michael Genz; James L Raper; Lori L DeLaitsch; Joseph M Mrus; winslow klaskala; Michael J Mugavero; Michael S Saag
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.
AIDS (London, England) 2009;23(12):1539-46.
2009: Benjamin H Chi; Ronald A Cantrell; Isaac Zulu; Lloyd B Mulenga; Jens W Levy; Bushimbwa C Tambatamba; Stewart Reid; Albert Mwango; Alwyn Mwinga; Marc Bulterys; Michael S Saag; Jeffrey S A Stringer
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia.
International journal of epidemiology 2009;38(3):746-56.
2009: Michael J Mugavero; Hui-Yi Lin; James H Willig; Andrew Westfall; Kimberly B Ulett; Justin S Routman; Sarah Abroms; James L Raper; Michael S Saag; Jeroan J Allison
Missed visits and mortality among patients establishing initial outpatient HIV treatment.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(2):248-56.
2009: Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan L Davies; Michael S Saag
Racial disparities in HIV virologic failure: do missed visits matter?
Journal of acquired immune deficiency syndromes (1999) 2009;50(1):100-8.
2009: Kimberly B Ulett; James H Willig; Hui-Yi Lin; Justin S Routman; Sarah Abroms; Jeroan Allison; Ashlee Chatham; James L Raper; Michael S Saag; Michael J Mugavero
The therapeutic implications of timely linkage and early retention in HIV care.
AIDS patient care and STDs 2009;23(1):41-9.
2008: Michael J Mugavero; Margaret May; Ross Harris; Michael S Saag; Dominique Costagliola; Matthias Egger; Andrew Phillips; Huldrych F Günthard; Francois Dabis; Hogg Robert; Frank de Wolf; Gerd Fatkenheuer; M John Gill; Amy Justice; Antonella d'Arminio Monforte; Fiona Lampe; Jose M Miró; Schlomo Staszewski; Jonathan A C Sterne
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
AIDS (London, England) 2008;22(18):2481-92.
2008: Lindsay S Robison; Andrew Westfall; Michael J Mugavero; Mirjam C Kempf; Stephen R Cole; Jeroan J Allison; James H Willig; James L Raper; C Mel Wilcox; Michael S Saag
Short-term discontinuation of HAART regimens more common in vulnerable patient populations.
AIDS research and human retroviruses 2008;24(11):1347-55.
2008: James H Willig; Sarah Abroms; Andrew Westfall; Justin Routman; Sunil Adusumilli; Mohit Varshney; Jeroan Allison; Ashlee Chatham; James L Raper; Richard A Kaslow; Michael S Saag; Michael J Mugavero
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
AIDS (London, England) 2008;22(15):1951-60.
2008: Lloyd B Mulenga; Gina Kruse; Shabir Lakhi; Ronald A Cantrell; Stewart E Reid; Isaac Zulu; Elizabeth M Stringer; Zipporah Krishnasami; Alwyn Mwinga; Michael S Saag; Jeffrey S A Stringer; Benjamin H Chi
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.
AIDS (London, England) 2008;22(14):1821-7.
2008: Jason D Goldman; Ronald A Cantrell; Lloyd B Mulenga; Bushimbwa C Tambatamba; Stewart E Reid; Jens W Levy; Mohammed Limbada; Angela Taylor; Michael S Saag; Sten Vermund; Jeffrey S A Stringer; Benjamin H Chi
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy.
AIDS research and human retroviruses 2008;24(8):1031-5.
2008: J. Michael Kilby; Ha Youn Lee; J Darren Hazelwood; Anju Bansal; R Pat Bucy; Michael S Saag; George M Shaw; Edward P Acosta; Victoria A Johnson; Alan S Perelson; Paul A Goepfert
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.
AIDS (London, England) 2008;22(8):957-62.
2008: James H Willig; David A Jackson; Andrew Westfall; Jeroan Allison; Pei-Wen Chang; James L Raper; Michael S Saag; Michael J Mugavero
Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(8):1315-8.
2008: Ruimin Tan; Andrew Westfall; James H Willig; Michael J Mugavero; Michael S Saag; Richard A Kaslow; Mirjam C Kempf
Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2008;47(5):553-8.
2008: Richard Davey; Peter E Pertel; Alice Benson; Delanie J Cassell; Brian G Gazzard; Mark Holodniy; Jacob P Lalezari; Yves Levy; Ronald T Mitsuyasu; Frank J Palella; Richard B Pollard; Prabhu Rajagopalan; Michael S Saag; Robert A Salata; Beverly E Sha; Shurjeel Choudhri
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(2):89-100.
2007: James H Willig; Andrew Westfall; Jeroan Allison; Nicholas Van Wagoner; Pei-Wen Chang; James L Raper; Michael S Saag; Michael J Mugavero
Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(5):658-61.
2007: Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; James H Willig; Pei-Wen Chang; Malcolm Marler; James L Raper; Joseph E Schumacher; Maria Pisu; Michael S Saag
Failure to establish HIV care: characterizing the "no show" phenomenon.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(1):127-30.
2007: Ray Y Chen; Andrew Westfall; J Michael Hardin; Cassandra Miller-Hardwick; Jeffrey S A Stringer; James L Raper; Sten Vermund; Eduardo Gotuzzo; Jeroan Allison; Michael S Saag
Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings.
Journal of acquired immune deficiency syndromes (1999) 2007;44(5):525-30.
2007: Michael J Mugavero; Michael S Saag
HIV care at a crossroads: the emerging crisis in the US HIV epidemic.
MedGenMed : Medscape general medicine 2007;9(1):58.
2007: Shashwatee Bagchi; Mirjam C Kempf; Andrew Westfall; Anastasiya Maherya; James H Willig; Michael S Saag
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(1):135-8.
2006: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; José M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2006;296(7):827-43.
2006: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
JAMA : the journal of the American Medical Association 2006;296(7):782-93.
2006: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; José M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):827-43.
2006: Michael S Saag
Ryan White CARE Act reauthorization: we need help.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(2):93-4.
2006: Michael S Saag
The experts speak. Burn-out among HIV care providers. Interview by Vicki Glaser.
AIDS patient care and STDs 2006;20(6):385-90.
2006: Ray Y Chen; Neil A Accortt; Andrew Westfall; Michael J Mugavero; James L Raper; Gretchen A Cloud; Beth K Stone; Jerome Carter; Stephanie Call; Maria Pisu; Jeroan Allison; Michael S Saag
Distribution of health care expenditures for HIV-infected patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(7):1003-10.
2006: Roger Bedimo; Ray Y Chen; Andrew Westfall; James L Raper; Jeroan J Allison; Michael S Saag
Sustained HIV viral suppression following treatment interruption: an observational study.
AIDS research and human retroviruses 2006;22(1):40-4.
2006: Michael S Saag
Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(1):126-31.
2005: Melissa S Dillmon; Michael S Saag; Sate Hamza; Brian K Adler; Marisa B Marques
Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature.
AIDS research and human retroviruses 2005;21(9):753-6.
2005: Julie M Decker; Frederic Bibollet-Ruche; Xiping Wei; shuyi wang; David N Levy; Wenquan Wang; Eric Delaporte; Martine Peeters; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Michael S Saag; James A Hoxie; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
The Journal of experimental medicine 2005;201(9):1407-19.
2005: Laura H Bachmann; Diane M Grimley; Yvonne Waithaka; Renee A Desmond; Michael S Saag; Edward W Hook
Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care.
Sexually transmitted diseases 2005;32(1):20-6.
2004: Roger Bedimo; Ray Y Chen; Neil A Accortt; James L Raper; Carol Linn; Jeroan J Allison; John Dubay; Michael S Saag; Craig J Hoesley
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(9):1380-4.
2004: Michael S Saag; Peter J Bowers; Gerhard Leitz; Alexandra M Levine
Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.
AIDS research and human retroviruses 2004;20(10):1037-45.
2004: Patrick G Yeni; Scott M Hammer; Martin S Hirsch; Michael S Saag; Mauro Schechter; Charles C J Carpenter; Margaret A Fischl; José M Gatell; Brian G Gazzard; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Paul A Volberding
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2004;292(2):251-65.
2004: Michael S Saag
Initiation of antiretroviral therapy: implications of recent findings.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2004;12(3):83-8.
2003: Eric S Goetzman; Liqun Tian; Tim Nagy; Barbara A Gower; Trenton R Schoeb; Ada Elgavish; Edward P Acosta; Michael S Saag; Philip A Wood
HIV protease inhibitor ritonavir induces lipoatrophy in male mice.
AIDS research and human retroviruses 2003;19(12):1141-50.
2003: Michael S Saag
Antiretroviral therapy: select lessons from recent studies.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(5):164-8.
2003: Ray Y Chen; Andrew Westfall; Michael J Mugavero; Gretchen A Cloud; James L Raper; Ashlee G Chatham; Edward P Acosta; Kelly H Taylor; Jerome Carter; Michael S Saag
Duration of highly active antiretroviral therapy regimens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(5):714-22.
2003: Xiping Wei; Julie M Decker; shuyi wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J. Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Antibody neutralization and escape by HIV-1.
Nature 2003;422(6929):307-12.
2002: Ray Y Chen; J. Michael Kilby; Michael S Saag
Enfuvirtide.
Expert opinion on investigational drugs 2002;11(12):1837-43.
2002: Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.
Journal of acquired immune deficiency syndromes (1999) 2002;31(3):257-75.
2002: T F Ferguson; KE Stewart; Ellen Funkhouser; Jerry M Tolson; Andrew Westfall; Michael S Saag
Patient-perceived barriers to antiretroviral adherence: associations with race.
AIDS care 2002;14(5):607-17.
2002: Ray Y Chen; Andrew Westfall; James L Raper; Gretchen A Cloud; Ashlee K Chatham; Edward P Acosta; Sissi V Pham; Jerry M Tolson; Gustavo R Heudebert; Michael S Saag
Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.
AIDS research and human retroviruses 2002;18(13):909-16.
2002: Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; José M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Paul A Volberding
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2002;288(2):222-35.
2002: J. Michael Kilby; Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Roberto C Arduino; Jeffrey C Goodgame; Joel E Gallant; Paul A Volberding; Robert L Murphy; Fred Valentine; Michael S Saag; Emily L Nelson; Prakash Sista; Alex Dusek
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
AIDS research and human retroviruses 2002;18(10):685-93.
2002: Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J. Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Antimicrobial agents and chemotherapy 2002;46(6):1896-905.
2001: M E Coghlan; J P Sommadossi; N C Jhala; W J Many; Michael S Saag; Victoria A Johnson
Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(11):1914-21.
2001: Michael S Saag; Pablo Tebas; Michael Sension; Marcus Conant; R Myers; S K Chapman; R Anderson; NJ Clendeninn
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
AIDS (London, England) 2001;15(15):1971-8.
2001: Barbara Gerbert; James Moe; Michael S Saag; Constance A Benson; Donna M Jacobsen; A Feraios; M E Hill; Amy Bronstone; Nona Caspers; Paul A Volberding
Toward a definition of HIV expertise: a survey of experienced HIV physicians.
AIDS patient care and STDs 2001;15(6):321-30.
2001: Michael S Saag
The impact of highly active antiretroviral therapy on HIV-specific immune function.
AIDS (London, England) 2001;15 Suppl 2():S4-10.
2001: Stephanie Call; Michael S Saag; Andrew Westfall; James L Raper; Sissi V Pham; Jerry M Tolson; N S Hellmann; Gretchen A Cloud; Victoria A Johnson
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.
The Journal of infectious diseases 2001;183(3):401-8.
2000: Craig J Hoesley; Michael S Saag; A Chatham; J. Michael Kilby
Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(4):1095-7.
2000: J. Michael Kilby; Greg Sfakianos; N Gizzi; P Siemon-Hryczyk; E Ehrensing; Charles Oo; N Buss; Michael S Saag
Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
Antimicrobial agents and chemotherapy 2000;44(10):2672-8.
2000: J. Michael Kilby; Paul A Goepfert; Andrew P Miller; John W Gnann; Michael J Sillers; Michael S Saag; R Pat Bucy
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.
Annals of internal medicine 2000;133(6):435-8.
2000: RD Hockett; Michael S Saag; J. Michael Kilby; Greg Sfakianos; T B Wakefield; R Pat Bucy
Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR.
Journal of virological methods 2000;87(1-2):1-12.
2000: Michael S Saag; R J Graybill; Robert A Larsen; Peter G Pappas; John R Perfect; William G Powderly; Jack D Sobel; William E Dismukes
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30(4):710-8.
2000: Charles C J Carpenter; D A Cooper; Margaret A Fischl; José M Gatell; Brian G Gazzard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(3):381-90.
2000: Stephanie Call; Joshua C Klapow; KE Stewart; Andrew Westfall; Alison P Mallinger; R A DeMasi; Robert M Centor; Michael S Saag
Health-related quality of life and virologic outcomes in an HIV clinic.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2000;9(9):977-85.
1999: Cynthia A Derdeyn; J. Michael Kilby; G Diego Miralles; L F Li; Greg Sfakianos; Michael S Saag; RD Hockett; R Pat Bucy
Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
The Journal of infectious diseases 1999;180(6):1851-62.
1999: Michael S Saag; W J Fessel; C A Kaufman; K W Merrill; D J Ward; BL Moskovitz; C Thomas; Napoleon A Oleka; JA Guarnieri; Jeannette Lee; L Brenner-Gati; M Klausner
Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.
AIDS research and human retroviruses 1999;15(16):1413-7.
1999: William G Powderly; Michael S Saag; S Chapman; G Yu; B Quart; NJ Clendeninn
Predictors of optimal virological response to potent antiretroviral therapy.
AIDS (London, England) 1999;13(14):1873-80.
1999: Cathal E O'Sullivan; W Lawrence Drew; D J McMullen; Richard C Miner; J Y Lee; Richard A Kaslow; J G Lazar; Michael S Saag
Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
The Journal of infectious diseases 1999;180(3):847-9.
1999: Cynthia A Derdeyn; Caroline Costello; J. Michael Kilby; Greg Sfakianos; Michael S Saag; Richard A Kaslow; R Pat Bucy
Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals.
AIDS research and human retroviruses 1999;15(12):1063-71.
1999: Michael S Saag; J. Michael Kilby
HIV-1 and HAART: a time to cure, a time to kill.
Nature medicine 1999;5(6):609-11.
1999: RD Hockett; J. Michael Kilby; Cynthia A Derdeyn; Michael S Saag; Michael J Sillers; K Squires; S Chiz; M A Nowak; George M Shaw; R Pat Bucy
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.
The Journal of experimental medicine 1999;189(10):1545-54.
1999: R Pat Bucy; RD Hockett; Cynthia A Derdeyn; Michael S Saag; K Squires; Michael J Sillers; Ronald T Mitsuyasu; J. Michael Kilby
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.
The Journal of clinical investigation 1999;103(10):1391-8.
1999: Michael S Saag; Gretchen A Cloud; John Graybill; Jack D Sobel; CU Tuazon; Philip C Johnson; W J Fessel; BL Moskovitz; B Wiesinger; D Cosmatos; L Riser; C Thomas; Richard Hafner; William E Dismukes
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(2):291-6.
1998: Michael S Saag; A Sonnerborg; R A Torres; Dan Lancaster; B G Gazzard; Robert T Schooley; C Romero; D Kelleher; William Spreen; Steve Lafon
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
AIDS (London, England) 1998;12(16):F203-9.
1998: J. Michael Kilby; S Hopkins; T M Venetta; B DiMassimo; Gretchen A Cloud; J Y Lee; L Alldredge; Eric Hunter; D Lambert; Dani P Bolognesi; Tom Matthews; M R Johnson; M A Nowak; George M Shaw; Michael S Saag
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
Nature medicine 1998;4(11):1302-7.
1998: Charles C J Carpenter; Margaret A Fischl; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 1998;280(1):78-86.
1998: Michael S Saag; Robert T Schooley
Antiretroviral chemotherapy.
Current clinical topics in infectious diseases 1998;18():154-79.
1997: J. Michael Kilby; Paul B Tabereaux; V Mulanovich; George M Shaw; R Pat Bucy; Michael S Saag
Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss.
AIDS research and human retroviruses 1997;13(17):1533-7.
1997: Charles van der Horst; Michael S Saag; Gretchen A Cloud; Richard J Hamill; John Graybill; Jack D Sobel; Philip C Johnson; CU Tuazon; T Kerkering; BL Moskovitz; William G Powderly; William E Dismukes
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
The New England journal of medicine 1997;337(1):15-21.
1997: Charles C J Carpenter; Margaret A Fischl; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 1997;277(24):1962-9.
1997: G B Craig; Betty E Darnell; Roland L Weinsier; Michael S Saag; L Epps; L Mullins; W I Lapidus; David M Ennis; S S Akrabawi; Phillip E Cornwell; HE Sauberlich
Decreased fat and nitrogen losses in patients with AIDS receiving medium-chain-triglyceride-enriched formula vs those receiving long-chain-triglyceride-containing formula.
Journal of the American Dietetic Association 1997;97(6):605-11.
1997: Michael S Saag
Candidate antiretroviral agents for use in postexposure prophylaxis.
The American journal of medicine 1997;102(5B):25-31.
1997: Michael S Saag
Use of virologic markers in clinical practice.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16 Suppl 1():S3-13.
1996: Michael S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; Donna M Jacobsen; George M Shaw; D D Richman; P A Volberding
HIV viral load markers in clinical practice.
Nature medicine 1996;2(6):625-9.
1996: J. Michael Kilby; Michael S Saag
Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
Advances in experimental medicine and biology 1996;394():291-8.
1995: John C Kappes; Michael S Saag; George M Shaw; Beatrice H Hahn; P Chopra; S Chen; Emilio A Emini; R McFarland; L C Yang; M Piatak
Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(2):139-49.
1995: Y Cao; David D Ho; J Todd; R Kokka; M Urdea; Jeffrey D Lifson; M Piatak; S Chen; Beatrice H Hahn; Michael S Saag
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.
AIDS research and human retroviruses 1995;11(3):353-61.
1994: J. Michael Kilby; Michael S Saag
Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
Infectious agents and disease 1994;3(6):313-23.
1994: Michael S Saag
Evolving understanding of the immunopathogenesis of HIV.
AIDS research and human retroviruses 1994;10(8):887-92.
1994: Feng Gao; Ling Yue; S C Hill; David L Robertson; A H Graves; Michael S Saag; George M Shaw; Paul M Sharp; Beatrice H Hahn
HIV-1 sequence subtype D in the United States.
AIDS research and human retroviruses 1994;10(5):625-7.
1993: M Piatak; Michael S Saag; L C Yang; S J Clark; John C Kappes; K C Luk; Beatrice H Hahn; George M Shaw; Jeffrey D Lifson
Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.
AIDS (London, England) 1993;7 Suppl 2():S65-71.
1993: Michael S Saag; Emilio A Emini; O L Laskin; J Douglas; W I Lapidus; William A Schleif; Richard J Whitley; C Hildebrand; V W Byrnes; John C Kappes
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.
The New England journal of medicine 1993;329(15):1065-72.
1993: S K Ghosh; P N Fultz; E Keddie; Michael S Saag; Paul M Sharp; Beatrice H Hahn; George M Shaw
A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes.
Virology 1993;194(2):858-64.
1993: M Piatak; L C Yang; K C Luk; Jeffrey D Lifson; Michael S Saag; S J Clark; John C Kappes; Beatrice H Hahn; George M Shaw
Viral dynamics in primary HIV-1 infection.
Lancet 1993;341(8852):1099.
1993: M Piatak; Michael S Saag; L C Yang; S J Clark; John C Kappes; K C Luk; Beatrice H Hahn; George M Shaw; Jeffrey D Lifson
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.
Science (New York, N.Y.) 1993;259(5102):1749-54.
1992: William E Dismukes; Robert W Bradsher; G C Cloud; Carol A Kauffman; Stanley W Chapman; R B George; D A Stevens; W M Girard; Michael S Saag; C Bowles-Patton
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.
The American journal of medicine 1992;93(5):489-97.
1992: Michael S Saag; W G Powderly; Gretchen A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; John F Fisher
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
The New England journal of medicine 1992;326(2):83-9.
1991: Michael S Saag; M J Crain; W D Decker; S Campbell-Hill; S Robinson; W E Brown; M Leuther; Richard J Whitley; Beatrice H Hahn; George M Shaw
High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
The Journal of infectious diseases 1991;164(1):72-80.
1991: S J Clark; Michael S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; John C Kappes; Beatrice H Hahn; George M Shaw
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
The New England journal of medicine 1991;324(14):954-60.
1988: Michael S Saag; William E Dismukes
Azole antifungal agents: emphasis on new triazoles.
Antimicrobial agents and chemotherapy 1988;32(1):1-8.
1986: M D Lyon; K R Smith; Michael S Saag; Gretchen A Cloud; C G Cobbs
In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1986;30(1):25-30.